Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study
- DOI
- 10.1016/j.annonc.2026.10.103
- Published
- 2026-10
- Container
- Annals of Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.annonc.2026.10.103,
title = {Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study},
author = {N. Girard and M. Burotto and L.G. Paz-Ares and M. Schenker and A. Lingua and F. Orlandi and J. Naidoo and E.K. Beardsley and V. Velcheti and G.L. Martinengo and E. Felip and M. Reck and A. Qureshi and P. Kasbekar and S. Samanta and J. Neely and Charlie Garnett-Benson and L. McDonald and J.X. Yu and M. Cobo-Dols},
year = {2026},
journal = {Annals of Oncology},
doi = {10.1016/j.annonc.2026.10.103},
url = {https://doi.org/10.1016/j.annonc.2026.10.103}
}RIS
TY - JOUR TI - Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study AU - N. Girard AU - M. Burotto AU - L.G. Paz-Ares AU - M. Schenker AU - A. Lingua AU - F. Orlandi AU - J. Naidoo AU - E.K. Beardsley AU - V. Velcheti AU - G.L. Martinengo AU - E. Felip AU - M. Reck AU - A. Qureshi AU - P. Kasbekar AU - S. Samanta AU - J. Neely AU - Charlie Garnett-Benson AU - L. McDonald AU - J.X. Yu AU - M. Cobo-Dols PY - 2026 JO - Annals of Oncology DO - 10.1016/j.annonc.2026.10.103 UR - https://doi.org/10.1016/j.annonc.2026.10.103 ER -
APA
Girard, N., Burotto, M., Paz-Ares, L., Schenker, M., Lingua, A., Orlandi, F., Naidoo, J., Beardsley, E., Velcheti, V., Martinengo, G., Felip, E., Reck, M., Qureshi, A., Kasbekar, P., Samanta, S., Neely, J., Garnett-Benson, C., McDonald, L., Yu, J., & Cobo-Dols, M. (2026). Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study. Annals of Oncology. https://doi.org/10.1016/j.annonc.2026.10.103
Source records
- crossref · retrieved 2026-11-06T05:46:42.730Z